Tiffiny S. Cooper

538 total citations
20 papers, 412 citations indexed

About

Tiffiny S. Cooper is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tiffiny S. Cooper has authored 20 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tiffiny S. Cooper's work include PARP inhibition in cancer therapy (9 papers), DNA Repair Mechanisms (6 papers) and Genital Health and Disease (3 papers). Tiffiny S. Cooper is often cited by papers focused on PARP inhibition in cancer therapy (9 papers), DNA Repair Mechanisms (6 papers) and Genital Health and Disease (3 papers). Tiffiny S. Cooper collaborates with scholars based in United States, Italy and Israel. Tiffiny S. Cooper's co-authors include Eddy S. Yang, Somaira Nowsheen, Alice N. Weaver, Jennifer Stanley, James A. Bonner, Eben L. Rosenthal, Albert F. LoBuglio, Hoa Q. Trummell, Ling Zeng and Shi Wei and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Tiffiny S. Cooper

19 papers receiving 408 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tiffiny S. Cooper United States 11 267 257 61 57 53 20 412
Michael S. Leibowitz United States 10 166 0.6× 315 1.2× 40 0.7× 106 1.9× 27 0.5× 14 505
Justin Wang United States 9 206 0.8× 144 0.6× 87 1.4× 45 0.8× 24 0.5× 12 430
Insoon Chang United States 8 392 1.5× 236 0.9× 155 2.5× 37 0.6× 13 0.2× 12 526
Gan Xiong China 12 220 0.8× 114 0.4× 94 1.5× 34 0.6× 14 0.3× 26 348
P. J. Slootweg Netherlands 6 192 0.7× 193 0.8× 74 1.2× 40 0.7× 64 1.2× 7 324
Ye‐Lin Liang China 12 410 1.5× 104 0.4× 304 5.0× 54 0.9× 39 0.7× 21 541
Jung Hwa Moon South Korea 8 267 1.0× 182 0.7× 117 1.9× 26 0.5× 16 0.3× 10 372
Kaisa Erjala Finland 7 158 0.6× 218 0.8× 36 0.6× 135 2.4× 88 1.7× 8 340
Lei Bian China 11 264 1.0× 137 0.5× 108 1.8× 32 0.6× 11 0.2× 18 398
Akihisa Kiyota Japan 10 161 0.6× 242 0.9× 48 0.8× 73 1.3× 67 1.3× 11 357

Countries citing papers authored by Tiffiny S. Cooper

Since Specialization
Citations

This map shows the geographic impact of Tiffiny S. Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tiffiny S. Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tiffiny S. Cooper more than expected).

Fields of papers citing papers by Tiffiny S. Cooper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tiffiny S. Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tiffiny S. Cooper. The network helps show where Tiffiny S. Cooper may publish in the future.

Co-authorship network of co-authors of Tiffiny S. Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of Tiffiny S. Cooper. A scholar is included among the top collaborators of Tiffiny S. Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tiffiny S. Cooper. Tiffiny S. Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zhang, Zhuo, Rajani Rajbhandari, Tiffiny S. Cooper, et al.. (2018). Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition. Molecular Cancer Therapeutics. 17(5). 921–930. 14 indexed citations
3.
Zeng, Ling, et al.. (2017). Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics. 16(4). 591–600. 40 indexed citations
4.
Yang, Eddy S., et al.. (2017). Combining Chk1/2 Inhibition With Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 99(2). S148–S149. 7 indexed citations
5.
Yang, Eddy S., Christopher D. Willey, Amitkumar Mehta, et al.. (2017). Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets. Oncotarget. 8(13). 21710–21718. 15 indexed citations
6.
Weaver, Alice N., Tiffiny S. Cooper, Shi Wei, et al.. (2016). Notch Signaling Activation Is Associated with Patient Mortality and Increased FGF1-Mediated Invasion in Squamous Cell Carcinoma of the Oral Cavity. Molecular Cancer Research. 14(9). 883–891. 33 indexed citations
7.
Rajbhandari, Rajani, et al.. (2016). Let-7 Status Is Crucial for PARP1 Expression in HER2-Overexpressing Breast Tumors. Molecular Cancer Research. 15(3). 340–347. 15 indexed citations
8.
Ghatalia, Pooja, Eddy S. Yang, Brittany N. Lasseigne, et al.. (2016). Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets. PLoS ONE. 11(8). e0160924–e0160924. 21 indexed citations
9.
Weaver, Alice N., Tiffiny S. Cooper, Shi Wei, et al.. (2016). DNA‐PkCS expression in oropharyngeal squamous cell carcinoma: Correlations with human papillomavirus status and recurrence after transoral robotic surgery. Head & Neck. 39(2). 206–214. 5 indexed citations
10.
Jones, Robert B., Patricia H. Hicks, Alice N. Weaver, et al.. (2016). MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell lines. Oncology Letters. 13(3). 1216–1222. 13 indexed citations
11.
Cooper, Tiffiny S., Andres Forero‐Torres, Francisco J. Esteva, et al.. (2015). Crosstalk between PARP-1 and NF-κB signaling pathways as a potential determinant of PARPi sensitivity in trastuzumab resistant HER2+ breast cancer cell lines.. Journal of Clinical Oncology. 33(15_suppl). 606–606. 1 indexed citations
12.
Mehta, Amitkumar, Eddy S. Yang, Andrea Necchi, et al.. (2015). Gene expression profiling to improve prognostic stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy.. Journal of Clinical Oncology. 33(15_suppl). e15633–e15633. 2 indexed citations
13.
Weaver, Alice N., Tiffiny S. Cooper, Hoa Q. Trummell, et al.. (2015). DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma. Oncotarget. 6(29). 26995–27007. 70 indexed citations
14.
Mehta, Amitkumar, Eddy S. Yang, Christopher D. Willey, et al.. (2015). Multiplatform comprehensive kinase analysis of penile squamous cell carcinoma (PSCC) to identify drivers and potentially actionable therapeutic targets.. Journal of Clinical Oncology. 33(7_suppl). 389–389. 2 indexed citations
15.
Isayeva, Tatyana, Jie Xu, Camille Ragin, et al.. (2014). The protective effect of p16INK4a in oral cavity carcinomas: p16Ink4A dampens tumor invasion—integrated analysis of expression and kinomics pathways. Modern Pathology. 28(5). 631–653. 27 indexed citations
16.
Whitley, Alexander C., Tiffiny S. Cooper, Anusha Angajala, et al.. (2014). Radiosensitization by erlotinib and veliparib in esophageal squamous cell cancer.. Journal of Clinical Oncology. 32(3_suppl). 70–70. 1 indexed citations
17.
Cooper, Tiffiny S., et al.. (2013). Abstract 635: PARP inhibition in HPV positive head and neck cancers.. Cancer Research. 73(8_Supplement). 635–635. 1 indexed citations
18.
Nowsheen, Somaira, Tiffiny S. Cooper, Jennifer Stanley, & Eddy S. Yang. (2012). Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells. PLoS ONE. 7(10). e46614–e46614. 91 indexed citations
19.
Nowsheen, Somaira, Tiffiny S. Cooper, James A. Bonner, Albert F. LoBuglio, & Eddy S. Yang. (2012). HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair. Cancer Research. 72(18). 4796–4806. 53 indexed citations
20.
Yang, Eddy S., Somaira Nowsheen, Tiffiny S. Cooper, Albert F. LoBuglio, & James A. Bonner. (2012). Susceptibility of HER2+ breast cancer cells to poly (ADP-ribose) polymerase (PARP) inhibition independent of an inherent DNA repair defect.. Journal of Clinical Oncology. 30(15_suppl). 621–621. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael S. Leibowitz Breakdown of academic impact, for papers by Justin Wang Breakdown of academic impact, for papers by Insoon Chang Breakdown of academic impact, for papers by Gan Xiong Breakdown of academic impact, for papers by P. J. Slootweg Breakdown of academic impact, for papers by Ye‐Lin Liang Breakdown of academic impact, for papers by Jung Hwa Moon Breakdown of academic impact, for papers by Kaisa Erjala Breakdown of academic impact, for papers by Lei Bian Breakdown of academic impact, for papers by Akihisa Kiyota
Rankless by CCL
2026